TY - JOUR A1 - Wunder, Juliane A1 - Pemp, Daniela A1 - Cecil, Alexander A1 - Mahdiani, Maryam A1 - Hauptstein, René A1 - Schmalbach, Katja A1 - Geppert, Leo N. A1 - Ickstadt, Katja A1 - Esch, Harald L. A1 - Dankekar, Thomas A1 - Lehmann, Leane T1 - Influence of breast cancer risk factors on proliferation and DNA damage in human breast glandular tissues: role of intracellular estrogen levels, oxidative stress and estrogen biotransformation JF - Archives of Toxicology N2 - Breast cancer etiology is associated with both proliferation and DNA damage induced by estrogens. Breast cancer risk factors (BCRF) such as body mass index (BMI), smoking, and intake of estrogen-active drugs were recently shown to influence intratissue estrogen levels. Thus, the aim of the present study was to investigate the influence of BCRF on estrogen-induced proliferation and DNA damage in 41 well-characterized breast glandular tissues derived from women without breast cancer. Influence of intramammary estrogen levels and BCRF on estrogen receptor (ESR) activation, ESR-related proliferation (indicated by levels of marker transcripts), oxidative stress (indicated by levels of GCLC transcript and oxidative derivatives of cholesterol), and levels of transcripts encoding enzymes involved in estrogen biotransformation was identified by multiple linear regression models. Metabolic fluxes to adducts of estrogens with DNA (E-DNA) were assessed by a metabolic network model (MNM) which was validated by comparison of calculated fluxes with data on methoxylated and glucuronidated estrogens determined by GC- and UHPLC-MS/MS. Intratissue estrogen levels significantly influenced ESR activation and fluxes to E-DNA within the MNM. Likewise, all BCRF directly and/or indirectly influenced ESR activation, proliferation, and key flux constraints influencing E-DNA (i.e., levels of estrogens, CYP1B1, SULT1A1, SULT1A2, and GSTP1). However, no unambiguous total effect of BCRF on proliferation became apparent. Furthermore, BMI was the only BCRF to indeed influence fluxes to E-DNA (via congruent adverse influence on levels of estrogens, CYP1B1 and SULT1A2). KW - metabolic network model KW - estrogens KW - human breast KW - multiple linear regression Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265343 SN - 1432-0738 VL - 96 IS - 2 ER - TY - JOUR A1 - Rosenbaum, Corinna A1 - Schick, Martin Alexander A1 - Wollborn, Jakob A1 - Heider, Andreas A1 - Scholz, Claus-Jürgen A1 - Cecil, Alexander A1 - Niesler, Beate A1 - Hirrlinger, Johannes A1 - Walles, Heike A1 - Metzger, Marco T1 - Activation of Myenteric Glia during Acute Inflammation In Vitro and In Vivo JF - PLoS One N2 - Background Enteric glial cells (EGCs) are the main constituent of the enteric nervous system and share similarities with astrocytes from the central nervous system including their reactivity to an inflammatory microenvironment. Previous studies on EGC pathophysiology have specifically focused on mucosal glia activation and its contribution to mucosal inflammatory processes observed in the gut of inflammatory bowel disease (IBD) patients. In contrast knowledge is scarce on intestinal inflammation not locally restricted to the mucosa but systemically affecting the intestine and its effect on the overall EGC network. Methods and Results In this study, we analyzed the biological effects of a systemic LPS-induced hyperinflammatory insult on overall EGCs in a rat model in vivo, mimicking the clinical situation of systemic inflammation response syndrome (SIRS). Tissues from small and large intestine were removed 4 hours after systemic LPS-injection and analyzed on transcript and protein level. Laser capture microdissection was performed to study plexus-specific gene expression alterations. Upon systemic LPS-injection in vivo we observed a rapid and dramatic activation of Glial Fibrillary Acidic Protein (GFAP)-expressing glia on mRNA level, locally restricted to the myenteric plexus. To study the specific role of the GFAP subpopulation, we established flow cytometry-purified primary glial cell cultures from GFAP promotor-driven EGFP reporter mice. After LPS stimulation, we analyzed cytokine secretion and global gene expression profiles, which were finally implemented in a bioinformatic comparative transcriptome analysis. Enriched GFAP+ glial cells cultured as gliospheres secreted increased levels of prominent inflammatory cytokines upon LPS stimulation. Additionally, a shift in myenteric glial gene expression profile was induced that predominantly affected genes associated with immune response. Conclusion and Significance Our findings identify the myenteric GFAP-expressing glial subpopulation as particularly susceptible and responsive to acute systemic inflammation of the gut wall and complement knowledge on glial involvement in mucosal inflammation of the intestine. KW - gene expression KW - gastrointestinal tract KW - inflammatory bowel disease KW - central nervous system KW - systemic inflammatory response syndrome KW - inflammation KW - astrocytes KW - cytokines Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146544 VL - 11 IS - 3 ER - TY - JOUR A1 - Kunz, Meik A1 - Liang, Chunguang A1 - Nilla, Santosh A1 - Cecil, Alexander A1 - Dandekar, Thomas T1 - The drug-minded protein interaction database (DrumPID) for efficient target analysis and drug development JF - Database N2 - The drug-minded protein interaction database (DrumPID) has been designed to provide fast, tailored information on drugs and their protein networks including indications, protein targets and side-targets. Starting queries include compound, target and protein interactions and organism-specific protein families. Furthermore, drug name, chemical structures and their SMILES notation, affected proteins (potential drug targets), organisms as well as diseases can be queried including various combinations and refinement of searches. Drugs and protein interactions are analyzed in detail with reference to protein structures and catalytic domains, related compound structures as well as potential targets in other organisms. DrumPID considers drug functionality, compound similarity, target structure, interactome analysis and organismic range for a compound, useful for drug development, predicting drug side-effects and structure–activity relationships. KW - drug-minded protein KW - database Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-147369 VL - 2016 ER - TY - JOUR A1 - Cecil, Alexander A1 - Rikanovic, Carina A1 - Ohlsen, Knut A1 - Liang, Chunguang A1 - Bernhardt, Jorg A1 - Oelschlaeger, Tobias A. A1 - Gulder, Tanja A1 - Bringmann, Gerd A1 - Holzgrabe, Ulrike A1 - Unger, Matthias A1 - Dandekar, Thomas T1 - Modeling antibiotic and cytotoxic effects of the dimeric isoquinoline IQ-143 on metabolism and its regulation in Staphylococcus aureus, Staphylococcus epidermidis and human cells N2 - Background: Xenobiotics represent an environmental stress and as such are a source for antibiotics, including the isoquinoline (IQ) compound IQ-143. Here, we demonstrate the utility of complementary analysis of both host and pathogen datasets in assessing bacterial adaptation to IQ-143, a synthetic analog of the novel type N,C-coupled naphthyl-isoquinoline alkaloid ancisheynine. Results: Metabolite measurements, gene expression data and functional assays were combined with metabolic modeling to assess the effects of IQ-143 on Staphylococcus aureus, Staphylococcus epidermidis and human cell lines, as a potential paradigm for novel antibiotics. Genome annotation and PCR validation identified novel enzymes in the primary metabolism of staphylococci. Gene expression response analysis and metabolic modeling demonstrated the adaptation of enzymes to IQ-143, including those not affected by significant gene expression changes. At lower concentrations, IQ-143 was bacteriostatic, and at higher concentrations bactericidal, while the analysis suggested that the mode of action was a direct interference in nucleotide and energy metabolism. Experiments in human cell lines supported the conclusions from pathway modeling and found that IQ-143 had low cytotoxicity. Conclusions: The data suggest that IQ-143 is a promising lead compound for antibiotic therapy against staphylococci. The combination of gene expression and metabolite analyses with in silico modeling of metabolite pathways allowed us to study metabolic adaptations in detail and can be used for the evaluation of metabolic effects of other xenobiotics. KW - Staphylococcus aureus Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68802 ER - TY - JOUR A1 - Cecil, Alexander A1 - Gentschev, Ivaylo A1 - Adelfinger, Marion A1 - Dandekar, Thomas A1 - Szalay, Aladar A. T1 - Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models JF - Bioengineered N2 - Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a promising approach for cancer therapy. Recently, we showed that the oncolytic vaccinia virus GLV-1h68 has a therapeutic potential in treating human prostate and hepatocellular carcinomas in xenografted mice. In this study, we describe the use of dynamic boolean modeling for tumor growth prediction of vaccinia virus-injected human tumors. Antigen profiling data of vaccinia virus GLV-1h68-injected human xenografted mice were obtained, analyzed and used to calculate differences in the tumor growth signaling network by tumor type and gender. Our model combines networks for apoptosis, MAPK, p53, WNT, Hedgehog, the T-killer cell mediated cell death, Interferon and Interleukin signaling networks. The in silico findings conform very well with in vivo findings of tumor growth. Similar to a previously published analysis of vaccinia virus-injected canine tumors, we were able to confirm the suitability of our boolean modeling for prediction of human tumor growth after virus infection in the current study as well. In summary, these findings indicate that our boolean models could be a useful tool for testing of the efficacy of VACV-mediated cancer therapy already before its use in human patients. KW - boolean modeling KW - oncolytic virus KW - human xenografted mouse models KW - cancer therapy Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200507 VL - 10 IS - 1 ER - TY - THES A1 - Cecil, Alexander [geb. Schmid] T1 - Metabolische Netzwerkanalysen für den Weg von xenobiotischen zu verträglichen antibiotischen Substanzen T1 - Metabolic network analysis for the path from xenobiotic to compliant antibiotic substances N2 - Durch das Auftreten neuer Stämme resistenter Krankheitserreger ist die Suche nach neuartigen Wirkstoffen gegen diese, sich ständig weiter ausbreitende Bedrohung, dringend notwendig. Der interdisziplinäre Sonderforschungsbereich 630 der Universität Würzburg stellt sich dieser Aufgabe, indem hier neuartige Xenobiotika synthetisiert und auf ihre Wirksamkeit getestet werden. Die hier vorgelegte Dissertation fügt sich hierbei nahtlos in die verschiedenen Fachbereiche des SFB630 ein: Sie stellt eine Schnittstelle zwischen Synthese und Analyse der Effekte der im Rahmen des SFB630 synthetisierten Isochinolinalkaloid-Derivaten. Mit den hier angewandten bioinformatischen Methoden wurden zunächst die wichtigsten Stoffwechselwege von S. epidermidis R62A, S. aureus USA300 und menschlicher Zellen in sogenannten metabolischen Netzwerkmodellen nachgestellt. Basierend auf diesen Modellen konnten Enzymaktivitäten für verschiedene Szenarien an zugesetzten Xenobiotika berechnet werden. Die hierfür benötigten Daten wurden direkt aus Genexpressionsanalysen gewonnen. Die Validierung dieser Methode erfolgte durch Metabolommessungen. Hierfür wurde S. aureus USA300 mit verschiedenen Konzentrationen von IQ-143 behandelt und gemäß dem in dieser Dissertation vorgelegten Ernteprotokoll aufgearbeitet. Die Ergebnisse hieraus lassen darauf schließen, dass IQ-143 starke Effekte auf den Komplex 1 der Atmungskette ausübt – diese Resultate decken sich mit denen der metabolischen Netzwerkanalyse. Für den Wirkstoff IQ-238 ergaben sich trotz der strukturellen Ähnlichkeiten zu IQ-143 deutlich verschiedene Wirkeffekte: Dieser Stoff verursacht einen direkten Abfall der Enzymaktivitäten in der Glykolyse. Dadurch konnte eine unspezifische Toxizität dieser Stoffe basierend auf ihrer chemischen Struktur ausgeschlossen werden. Weiterhin konnten die bereits für IQ-143 und IQ-238 auf Bakterien angewandten Methoden erfolgreich zur Modellierung der Effekte von Methylenblau auf verschiedene resistente Stämme von P. falciparum 3D7 angewandt werden. Dadurch konnte gezeigt werden, dass Methylenblau in einer Kombination mit anderen Präparaten gegen diesen Parasiten zum einen die Wirkung des Primärpräparates verstärkt, zum anderen aber auch in gewissem Maße vorhandene Resistenzen gegen das Primärpräparat zu verringern vermag. Somit konnte durch die vorgelegte Arbeit eine Pipeline zur Identifizierung der metabolischen Effekte verschiedener Wirkstoffe auf unterschiedliche Krankheitserreger erstellt werden. Diese Pipeline kann jederzeit auf andere Organismen ausgeweitet werden und stellt somit einen wichtigen Ansatz um Netzwerkeffekte verschiedener, potentieller Medikamente aufzuklären. N2 - With the emergence of new strains of resistant pathogens, the search for new compounds against this spreading threat is of utmost importance. The interdisciplinary special research field SFB630 of the University of Würzburg is ready to tackle this task by synthesizing and analysing the effects of xenobiotics. The presented dissertation is seamlessly integrated into the diverse range of special fields of the SFB630: it provides a gateway between synthesis and analysis of the effects of the newly synthesized isoquinoline alkaloid derivatives. The presented bioinformatic methods were used to build a so called metabolic network model of the most important pathways of S. epidermidis RP62A, S. aureus USA300 and human cells. Based on these models it was possible to calculate the enzyme activities for different scenarios of added xenobiotics. The data needed for these calculations were derived directly from gene expression analysis. Validation of this method was done by metabolomic measurements. In order to accomplish this, a strain of S. aureus USA300 was subjected to different concentrations of IQ-143 and processed according to the workflow also published in this dissertation. The results suggest that IQ-143 has very strong effects on the complex 1 of the oxidative phosphorylation – these results are consistent with the results obtained by the metabolic network analysis. Although IQ-238 is structurally a close relative to IQ-143, the effects of this compound are very different: it leads to a drop of the enzyme activities in the glycolysis. Therefore an unspecific toxicity of those compounds based on their chemical structure dould be ruled out. The methods used to model the effects of IQ-143 and IQ-238 on bacteria were furthermore successfully transferred to model the effects of methylene blue on several resistant strains of P. falciparum 3D7. It was shown that a combination of methylene blue and other malaria medications either enhances the effects of the primary medication, or – in the case of a resistant strain – methylene blue was able to mitigate the resistances against the primary medication. The presented dissertation was thus successfully able to build a pipeline to identify the metabolic effects of different compounds on various germs. This pipeline can be expanded to other organisms at any time and therefore yields an important approach to identify network effects of various potential drugs. KW - Stoffwechsel KW - Bioinformatik KW - Mathematisches Modell KW - Enzymaktivität KW - Xenobiotikum KW - Netzwerkanalyse KW - Bioinformatik KW - Metabolische Stoffwechselmodellierung KW - Metabolomik KW - Metabonomik KW - Network analysis KW - Bioinformatics KW - metabolic pathway modeling KW - metabolomics KW - metabonomics Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-71866 ER - TY - JOUR A1 - Adelfinger, Marion A1 - Bessler, Simon A1 - Cecil, Alexander A1 - Langbein-Laugwitz, Johanna A1 - Frentzen, Alexa A1 - Gentschev, Ivaylo A1 - Szalay, Aladar A. T1 - Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy JF - Viruses N2 - Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS. KW - canine cancer therapy KW - canine soft tissue sarcoma (CSTS) KW - oncolytic virus KW - cancer KW - canine cancer cell lines KW - antibody production KW - angiogenesis Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125705 VL - 7 ER -